{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:52:50Z","timestamp":1789102370792,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Antiangiogenic therapy has proved to be an important therapeutic tool for many retinal vascular diseases; however, its availability is limited in developing countries. This study sought to describe the bevacizumab vial sharing process and to evaluate the impact of this repackaging system on the costs incurred in a Brazilian public hospital.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>This retrospective study compared the number and costs of intravitreal antiangiogenic injections approved via court order in the first year of the study (2015) to the number and costs of the bevacizumab injections provided through the use of vial sharing in the second year of the study (2016).<\/jats:p>\n                <jats:p>Vial sharing consists of the traditional process used to repackage bevacizumab; in this case, however, the drug samples used were the residual volume from the preparation of bevacizumab for oncology patients. The hospital adhered to the guidelines established by the Brazilian Health Surveillance Agency (ANVISA).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the first year of the study and using medication obtained through court orders, 550 intravitreal injections were performed in the ophthalmology ambulatory care center. Based on local pricing tables, the total cost of the medication was BRL$1,036,056.25 (USD$267,546.58), and the average cost of each application was BRL$1883.74 (USD$486.45).<\/jats:p>\n                <jats:p>In the second year of the study, 1081 intravitreal applications were performed at the same hospital using doses obtained through bevacizumab vial sharing. The total cost was BRL$21,942.49 (USD$5663.30) and the per-unit cost was BRL$20.30, or USD$5.23 (a savings of 97.88%).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study found that bevacizumab vial sharing led to a significant reduction in public health care costs associated with antiangiogenic treatment and increased the availability of the drug to public health care patients. These results can be extrapolated to other types of drugs and health care systems.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-019-7562-y","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T15:02:57Z","timestamp":1568214177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Costs and benefits of bevacizumab vial sharing for the treatment of retinal diseases"],"prefix":"10.1186","volume":"19","author":[{"given":"S\u00e1vio Lima","family":"Sodr\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italo Antunes Fran\u00e7a","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel Emiliano","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe de Queiroz Tavares","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton Agrizzi","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio Abujamra","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Eduardo Leite","family":"Arieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Paulo Cabral de","family":"Vasconcellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,11]]},"reference":[{"issue":"6","key":"7562_CR1","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/ICU.0000000000000424","volume":"28","author":"S Cai","year":"2017","unstructured":"Cai S, Bressler NM. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. Curr Opin Ophthalmol. 2017;28(6):636\u201343.","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"7562_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ophtha.2015.09.002","volume":"123","author":"SD Solomon","year":"2016","unstructured":"Solomon SD, Lindsley KB, Krzystolik MG, Vedula SS, Hawkins BS. Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration: findings from a cochrane systematic review. Ophthalmology. 2016;123(1):70\u20137.","journal-title":"Ophthalmology"},{"issue":"20","key":"7562_CR3","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL,Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related maculardegeneration. N Engl J Med 2011;364(20):1897\u20131908.","journal-title":"N Engl J Med"},{"key":"7562_CR4","unstructured":"Pan-American Retina and Vitreous Society. The Angiogenesis Foundation. Advocating for Improved Treatment and Outcomes for Wet Age-Related Macular Degeneration. In: A Report based on a Latin American Expert Summit convened in Bogota. Colombia, March. 2012. \n                    https:\/\/angio.org\/wp-content\/uploads\/2013\/10\/Latin_America_AMD_Expert_Summit_White_Paper-English.pdf\n                    \n                  . Accessed 17 Jan 2017."},{"key":"7562_CR5","unstructured":"Pesquisa nacional de sa\u00fade. Acesso e utiliza\u00e7\u00e3o dos servi\u00e7os de sa\u00fade, acidentes e viol\u00eancias. IBGE. Brazil. 2015. \n                    https:\/\/biblioteca.ibge.gov.br\/visualizacao\/livros\/liv94074.pdf\n                    \n                  . Accessed 20 Oct 2017."},{"issue":"16","key":"7562_CR6","doi-asserted-by":"publisher","first-page":"21247","DOI":"10.18632\/oncotarget.6918","volume":"7","author":"M Arjaans","year":"2016","unstructured":"Arjaans M, Schr\u00f6der CP, Oosting SF, Dafni U, Kleibeuker JE. de Vries EG. VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget. 2016;7(16):21247\u201358.","journal-title":"Oncotarget"},{"issue":"7","key":"7562_CR7","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/bjophthalmol-2014-306543","volume":"99","author":"R Narayanan","year":"2015","unstructured":"Narayanan R, Panchal B, Das T, Chhablani J, Jalali S, Ali MH. MARVEL study group. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1. Br J Ophthalmol. 2015;99(7):954\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"7562_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/jamaophthalmol.2015.4110","volume":"134","author":"JS Heier","year":"2016","unstructured":"Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, Dugel PU, Freund KB, Glassman AR, Kim JE, Martin DF, Pollack JS, Regillo CD, Rosenfeld PJ, Schachat AP. Wells JA 3rd; American Society of Retina Specialists Anti-VEGF for Diabetic Macular Edema Comparative Effectiveness Panel. Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice. JAMA Ophthalmol. 2016;134(1):95\u20139.","journal-title":"JAMA Ophthalmol"},{"issue":"78","key":"7562_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19780","volume":"19","author":"U Chakravarthy","year":"2015","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downes S, Lotery AJ, Dakin HA, Culliford L, Scott LJ, Nash RL, Taylor J, Muldrew A, Sahni J, Wordsworth S, Raftery J, Peto T. Reeves BC. A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to inhibit VEGF in age-related choroidal neovascularisation (IVAN). Health Technol Assess. 2015;19(78):1\u2013298.","journal-title":"Health Technol Assess"},{"issue":"9","key":"7562_CR10","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1136\/bjo.2007.116616","volume":"91","author":"J Raftery","year":"2007","unstructured":"Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol. 2007;91(9):1244\u20136.","journal-title":"Br J Ophthalmol"},{"key":"7562_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12886-015-0043-x","volume":"15","author":"AM Schauwvlieghe","year":"2015","unstructured":"Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Van Leeuwen R, Vingerling JR, Moll AC, Schlingemann RO. Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with diabetic macular edema: a randomized clinical trial (the BRDME study). BMC Ophthalmol. 2015;15:71.","journal-title":"BMC Ophthalmol"},{"issue":"8","key":"7562_CR12","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","volume":"134","author":"EL Ross","year":"2016","unstructured":"Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR. Diabetic Retinopathy Clinical Research Network. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. JAMA Ophthalmol. 2016;134(8):888\u201396.","journal-title":"JAMA Ophthalmol"},{"key":"7562_CR13","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Resolu\u00e7\u00e3o de Diretoria Colegiada 111. Minist\u00e9rio da Sa\u00fade, Brazil.2016. \n                    http:\/\/portal.anvisa.gov.br\/documents\/10181\/2971795\/RDC_111_2016_.pdf\n                    \n                  . Accessed 27 Nov 2017."},{"key":"7562_CR14","unstructured":"Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS. Ranibizumabe para Degenera\u00e7\u00e3o Macular Relacionada \u00e0 Idade. Minist\u00e9rio da Sa\u00fade, Brazil. 2015. \n                    http:\/\/conitec.gov.br\/images\/Relatorios\/2015\/Relatorio_Ranibizumabe_DMRI_final.pdf\n                    \n                  . Accessed 14 Dec 2017."},{"key":"7562_CR15","unstructured":"Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS. Antiangiog\u00eanicos (bevacizumbe e ranibizumabe) no tratamento do edema macular diab\u00e9tico. Minist\u00e9rio da Sa\u00fade, Brazil. 2015. \n                    http:\/\/conitec.gov.br\/images\/Consultas\/Relatorios\/2015\/Relatorio_Antiangiogenicos.pdf\n                    \n                  . Acessed 17 Dec 2017."},{"key":"7562_CR16","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Regulamento T\u00e9cnico Que Institui As Boas Pr\u00e1ticas De Manipula\u00e7\u00e3o Em Farm\u00e1cias. In: Resolu\u00e7\u00e3o De Diretoria Colegiada RDC 67, Minist\u00e9rio da Saude. Brazil. 2007. \n                    http:\/\/portal.anvisa.gov.br\/documents\/10181\/2718376\/RDC_67_2007_COMP.pdf\/5de28862-e018-4287-892e-a2add589ac26\n                    \n                  . Accessed 28 May 2016."},{"key":"7562_CR17","doi-asserted-by":"crossref","unstructured":"VANNI, Tazio et al . Avalia\u00e7\u00e3o econ\u00f4mica em sa\u00fade: aplica\u00e7\u00f5es em doen\u00e7as infecciosas. Cad. Sa\u00fade P\u00fablica, Rio de Janeiro, 25, 12, 2543-2552, 2009. http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0102-311X2009001200002&lng=en&nrm=iso>. Accessed 01 Aug 2019.","DOI":"10.1590\/S0102-311X2009001200002"},{"key":"7562_CR18","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Prec\u0327os ma\u0301ximos de medicamentos por princi\u0301pio ativo, para compras pu\u0301blicas. Prec\u0327o fa\u0301brica (PF) e prec\u0327o ma\u0301ximo de venda ao governo (PMVG). C\u00e2mara de Regula\u00e7\u00e3o - CMED. Brazil. 2016. \n                    http:\/\/portal.anvisa.gov.br\/documents\/374947\/2829072\/LISTA_CONFORMIDADE_GOV_2016-07-21.pdf\/f872c689-271c-444f-aa96-aaef31e865d8\n                    \n                  . Accessed 05 Dec 2017."},{"key":"7562_CR19","unstructured":"Yahii. Dolar comercial oficial. http:\/\/www.yahii.com.br\/dolar.html. Acessed 12 july 2018."},{"key":"7562_CR20","unstructured":"DGRH. Tabela de vencimentos. \n                    www.dgrh.unicamp.br\/documentos\/tabelas-de-vencimentos\/profissional-de-apoio-ao-ensino-pesquisa-e-extensao\n                    \n                  . Acessed 28 Feb 2019."},{"key":"7562_CR21","doi-asserted-by":"publisher","first-page":"i788","DOI":"10.1136\/bmj.i788","volume":"352","author":"PB Bach","year":"2016","unstructured":"Bach PB, Conti RM, Muller RJ, Schnorr GC, Saltz LB. Overspending driven by oversized single dose vials of cancer drugs. BMJ. 2016;352:i788.","journal-title":"BMJ"},{"issue":"1","key":"7562_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/jop.2008.0043","volume":"25","author":"YH Chen","year":"2009","unstructured":"Chen YH, Wu PC, Shiea J, Lo LH, Wu YC, Kuo HK. Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months. J Ocul Pharmacol Ther. 2009;25(1):65\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"key":"7562_CR23","unstructured":"Posicionamento oficial. Roche. 2016. \n                    http:\/\/www.roche.com.br\/home\/imprensa\/2016\/posicionamento-oficial-avastin-bevacizumabe.html\n                    \n                  . Accessed 21 Aug 2017."},{"key":"7562_CR24","doi-asserted-by":"crossref","unstructured":"Vasconcelos, Ana Maria Nogales, & Gomes, Mar\u00edlia Miranda Forte. Transi\u00e7\u00e3o demogr\u00e1fica: a experi\u00eancia brasileira. Epidemiologia e Servi\u00e7os de Sa\u00fade. 2012;21(4). \n                    https:\/\/dx.doi.org\/10.5123\/S1679-49742012000400003\n                    \n                  .","DOI":"10.5123\/S1679-49742012000400003"},{"issue":"3","key":"7562_CR25","first-page":"186","volume":"40","author":"NK Jos\u00e9","year":"1994","unstructured":"Jos\u00e9 NK, Delgado AM, Arieta CE. Practicability of cataract surgery at university hospitals: searching for an economic model. Rev Assoc Med Bras (1992). 1994;40(3):186\u20138.","journal-title":"Rev Assoc Med Bras (1992)"},{"issue":"7","key":"7562_CR26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1056\/NEJM200002173420707","volume":"342","author":"SL Fine","year":"2000","unstructured":"Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. N Engl J Med. 2000;342(7):483\u201392.","journal-title":"N Engl J Med"},{"issue":"1","key":"7562_CR27","first-page":"182","volume":"36","author":"R Klein","year":"1995","unstructured":"Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci. 1995;36(1):182\u201391.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"7562_CR28","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","volume":"27","author":"S Wild","year":"2004","unstructured":"Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047\u201353.","journal-title":"Diabetes Care"},{"issue":"1","key":"7562_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0161-6420(95)31052-4","volume":"102","author":"R Klein","year":"1995","unstructured":"Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102(1):7\u201316.","journal-title":"Ophthalmology"},{"key":"7562_CR30","unstructured":"Diretrizes da Sociedade Brasileira de Diabetes: 2014\u20132015. \n                    https:\/\/www.diabetes.org.br\/publico\/images\/2015\/area-restrita\/diretrizes-sbd-2015.pdf\n                    \n                  . Accessed 16 May 2018."},{"key":"7562_CR31","doi-asserted-by":"publisher","first-page":"f1049","DOI":"10.1136\/bmj.f1049","volume":"346","author":"H Don","year":"2013","unstructured":"Don H, Michael D, Stavros P, Chris C, David M, Dan G, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ. 2013;346:f1049.","journal-title":"BMJ"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-019-7562-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12889-019-7562-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-019-7562-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T16:55:00Z","timestamp":1599756900000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-019-7562-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,11]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["7562"],"URL":"https:\/\/doi.org\/10.1186\/s12889-019-7562-y","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,11]]},"assertion":[{"value":"29 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local Research Ethics Committee CEP (Comit\u00ea de \u00c9tica em Pesquisa) under committee registry number CAAE (Certificado de Apresenta\u00e7\u00e3o para Aprecia\u00e7\u00e3o \u00c9tica) 60695516.1.0000.5404. on January 16, 2018.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No consent to publish was needed for this study, as we did not use any personal information, images or videos of individual participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1252"}}